Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese aspirin

This article was originally published in The Tan Sheet

Executive Summary

International Trade Administration postpones preliminary determination on Chinese aspirin "dumping" until Dec. 21. The Commerce Department announced the bulk aspirin antidumping duty investigation in June, with a preliminary determination due by Nov. 4. ITA delayed its preliminary findings at the request of Cranbury, N.J.-based bulk aspirin manufacturer Rhodia, a Rhone-Poulenc S.A. subsidiary, which is seeking the imposition of antidumping duties on bulk aspirin imports from the People's Republic of China (1"The Tan Sheet" June 14, p. 9)

You may also be interested in...

Chinese Aspirin "Dumping" Is Under Trade Commission Investigation

The International Trade Commission is instituting an investigation into evidence of possible Chinese aspirin "dumping" onto the U.S. market, the commission announced in the Federal Register June 7. The investigation follows a May 28 petition from bulk aspirin manufacturer Rhodia requesting the "imposition of antidumping duties on imports of bulk aspirin from the People's Republic of China."

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts